Trial Profile
A Phase 3, Randomized, Open Label, Active-controlled Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of IV Peramivir Compared to Oral Oseltamivir in Pediatric Subjects With Acute Uncomplicated Influenza
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Apr 2021
Price :
$35
*
At a glance
- Drugs Peramivir (Primary) ; Oseltamivir
- Indications Influenza virus infections
- Focus Adverse reactions; Registrational
- Sponsors BioCryst Pharmaceuticals
- 27 May 2020 Status changed from recruiting to completed.
- 01 Aug 2019 Planned End Date changed from 1 Dec 2019 to 1 Oct 2021.
- 01 Aug 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Apr 2021.